RCUS [NYSE]
Arcus Biosciences, Inc.
Index- P/E- EPS (ttm)-0.01 Insider Own1.10% Shs Outstand71.19M Perf Week3.65%
Market Cap1.71B Forward P/E- EPS next Y-4.54 Insider Trans-4.81% Shs Float48.15M Perf Month34.18%
Income57.40M PEG- EPS next Q-0.94 Inst Own68.80% Short Float14.62% Perf Quarter-33.10%
Sales391.40M P/S4.37 EPS this Y131.90% Inst Trans-0.41% Short Ratio4.88 Perf Half Y-44.37%
Book/sh11.19 P/B2.18 EPS next Y-14.00% ROA4.70% Target Price57.20 Perf Year-15.91%
Cash/sh17.31 P/C1.41 EPS next 5Y- ROE8.20% 52W Range16.74 - 49.10 Perf YTD-39.66%
Dividend- P/FCF3.90 EPS past 5Y29.60% ROI6.20% 52W High-50.26% Beta0.75
Dividend %- Quick Ratio7.80 Sales past 5Y- Gross Margin- 52W Low45.88% ATR1.61
Employees366 Current Ratio7.80 Sales Q/Q89.50% Oper. Margin15.30% RSI (14)56.80 Volatility7.09% 7.51%
OptionableYes Debt/Eq0.00 EPS Q/Q11.70% Profit Margin14.70% Rel Volume0.36 Prev Close25.31
ShortableYes LT Debt/Eq0.00 EarningsMay 09 AMC Payout0.00% Avg Volume1.44M Price24.42
Recom1.70 SMA2010.26% SMA506.85% SMA200-25.20% Volume518,185 Change-3.52%
Oct-15-21Resumed BTIG Research Buy $57
Nov-24-20Initiated Berenberg Buy $50
Nov-23-20Initiated Evercore ISI Outperform
Apr-03-20Initiated Cantor Fitzgerald Overweight $21
Mar-04-20Initiated Barclays Overweight $24
Nov-12-19Initiated SunTrust Buy $20
Sep-27-19Initiated Mizuho Buy $22
May-24-19Resumed Citigroup Buy $25
Oct-09-18Initiated Wedbush Outperform $22
Apr-09-18Initiated Leerink Partners Outperform $21
Apr-09-18Initiated Goldman Neutral $18
Apr-09-18Initiated Citigroup Buy $18
Jun-25-22 10:44AM  
Jun-24-22 04:10PM  
Jun-09-22 04:10PM  
May-31-22 04:05PM  
May-24-22 04:10PM  
May-12-22 09:57AM  
May-11-22 04:09PM  
09:49AM  
May-10-22 04:10PM  
May-09-22 05:55PM  
04:03PM  
Apr-26-22 04:30PM  
04:10PM  
Apr-20-22 06:45AM  
Apr-11-22 04:10PM  
Apr-05-22 02:55PM  
07:26AM  
Apr-04-22 06:45PM  
Mar-24-22 04:10PM  
Mar-09-22 04:10PM  
Mar-08-22 04:30PM  
Feb-24-22 04:10PM  
Feb-23-22 06:45PM  
04:05PM  
Feb-15-22 04:10PM  
Feb-09-22 05:04PM  
Feb-07-22 01:12PM  
Feb-01-22 05:08PM  
Jan-28-22 05:38PM  
Jan-25-22 04:10PM  
Jan-14-22 11:42AM  
Jan-11-22 04:10PM  
Jan-10-22 08:00AM  
Dec-24-21 04:10PM  
Dec-22-21 07:15PM  
Dec-21-21 04:35PM  
04:35PM  
12:15AM  
Dec-14-21 04:05PM  
Dec-09-21 04:10PM  
08:20AM  
Nov-30-21 01:00AM  
Nov-26-21 08:46AM  
Nov-24-21 04:10PM  
Nov-22-21 04:10PM  
Nov-21-21 08:21PM  
Nov-19-21 09:43AM  
Nov-18-21 04:18PM  
09:53AM  
08:44AM  
07:38AM  
07:00AM  
Nov-15-21 06:01AM  
Nov-09-21 04:10PM  
Nov-08-21 06:25PM  
04:10PM  
01:15PM  
Nov-02-21 04:10PM  
Oct-28-21 03:05PM  
Oct-26-21 04:10PM  
Oct-25-21 10:01AM  
Oct-11-21 04:10PM  
Sep-27-21 04:10PM  
Sep-09-21 04:10PM  
Sep-01-21 04:10PM  
Aug-24-21 04:10PM  
Aug-10-21 04:10PM  
Aug-08-21 03:54AM  
Aug-05-21 08:45PM  
04:10PM  
Jul-29-21 04:10PM  
03:05PM  
Jul-26-21 04:10PM  
Jul-20-21 04:01PM  
Jul-13-21 09:07AM  
Jul-12-21 04:10PM  
Jul-02-21 05:54AM  
Jun-25-21 08:45AM  
06:29AM  
Jun-24-21 04:16PM  
04:10PM  
11:54AM  
09:42AM  
Jun-23-21 04:10PM  
Jun-09-21 04:10PM  
May-25-21 04:10PM  
May-19-21 05:05PM  
May-11-21 04:10PM  
May-05-21 08:15PM  
04:10PM  
May-01-21 07:31PM  
Apr-26-21 04:10PM  
Apr-10-21 08:33AM  
Apr-09-21 04:10PM  
Apr-03-21 04:10AM  
Mar-24-21 04:15PM  
Mar-12-21 12:24PM  
Mar-09-21 04:10PM  
Mar-04-21 12:13AM  
Feb-28-21 02:09AM  
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Tang Carolyn C.General CounselJun 17Sale22.121,52233,66523,909Jun 21 04:23 PM
Jaen Juan C.PresidentJun 17Sale22.122,53756,116210,037Jun 21 04:18 PM
Jarrett JenniferChief Operating OfficerJun 17Sale22.126,614146,294118,619Jun 21 04:19 PM
ROSEN TERRY JChief Executive OfficerJun 17Sale22.124,613102,034227,716Jun 21 04:21 PM
ROSEN TERRY JChief Executive OfficerJun 16Sale20.724,24187,874232,329Jun 21 04:21 PM
Jarrett JenniferChief Operating OfficerJun 16Sale20.726,081125,998125,233Jun 21 04:19 PM
Jaen Juan C.PresidentJun 16Sale20.722,33348,340212,574Jun 21 04:18 PM
Tang Carolyn C.General CounselJun 16Sale20.721,40029,00825,431Jun 21 04:23 PM
Jarrett JenniferChief Operating OfficerMar 16Sale31.629,617304,090105,978Mar 18 04:43 PM
Jarrett JenniferChief Operating OfficerDec 20Sale41.4834,8221,444,36990,595Dec 22 05:03 PM
ROSEN TERRY JChief Executive OfficerDec 17Sale40.362,943118,771211,570Dec 20 04:16 PM
Jarrett JenniferChief Operating OfficerDec 17Sale40.367,118287,261125,417Dec 20 04:17 PM
Jaen Juan C.PresidentDec 17Sale40.361,10844,715201,157Dec 20 04:19 PM
Goeltz II Robert C.Chief Financial OfficerDec 17Sale40.3662125,0617,019Dec 20 04:22 PM
Tang Carolyn C.General CounselDec 17Sale40.3662225,10217,564Dec 20 04:26 PM
Tang Carolyn C.General CounselDec 16Sale39.8248719,39418,186Dec 20 04:26 PM
Goeltz II Robert C.Chief Financial OfficerDec 16Sale39.8348519,3157,640Dec 20 04:22 PM
Jaen Juan C.PresidentDec 16Sale39.8286534,448202,265Dec 20 04:19 PM
Jarrett JenniferChief Operating OfficerDec 16Sale39.825,560221,423132,535Dec 20 04:17 PM
ROSEN TERRY JChief Executive OfficerDec 16Sale39.822,29991,556214,513Dec 20 04:16 PM
Jarrett JenniferChief Operating OfficerSep 21Sale35.6416,866601,088112,843Sep 22 04:32 PM
Jarrett JenniferChief Operating OfficerSep 20Sale35.1830,6341,077,826129,709Sep 22 04:32 PM